Skip to main content

Table 1 Patient baseline clinical characteristics

From: Virological response to daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study

Characteristics   All patients
N   30
Age, years   65.5 ± 7.7
Sex, male n (%) 23 (76.7)
Duration of hemodialysis years 15.4 ± 10.5
Etiology of end-stage renal disease n (%)  
 Diabetic nephropathy   13 (43.3)
 Polycystic kidney disease   2 (6.7)
 Interstitial nephritis   3 (10.0)
 Glomerulonephritis   7 (23.3)
 Others   5 (16.7)
Weight kg 51.2 ± 10.1
Previous treatment n (%)  
 Naïve   21 (70.0)
 Relapse   5 (16.6)
 Non-viral response   4 (13.3)
Liver cirrhosis n (%) 9 (30.0)
Serum HCV-RNA levels log10IU/mL 5.15 ± 0.95
NS5A inhibitor RAVs n (%) 2 (6.7)
Laboratory data
 Hemoglobin g/dL 10.6 ± 1.50
 WBC /μL 5484 ± 1760
 Neutrophils /μL 3718 ± 1381
 Platelets ×104/μL 16.5 ± 6.38
 Serum AST IU/L 20.1 ± 13.1
 Serum ALT IU/L 16.1 ± 8.21
 Serum albumin g/dL 3.40 ± 0.35
 BUN mg/dL 51.9 ± 16.5
 Serum creatinine mg/dL 9.31 ± 2.39
 Serum total bilirubin mg/dL 0.36 ± 0.16
 Alpha-fetoprotein ng/mL 2.39 ± 0.98
  1. Data are expressed as median, number (%), or mean ± standard deviation
  2. RAVs resistance-associated variants, BUN blood urea nitrogen, PT-INR international normalized ratio of prothrombin time